Dianthus advances DNTH103 in Phase 2 trial for gMG By Investing.com
[ad_1] © Reuters. NEW YORK and WALTHAM, Mass. – Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a biotechnology firm focused on autoimmune disease therapies, announced the start...